Bridgewater-based Cosette Pharmaceuticals on Wednesday said it acquired sleep medications Ambien and Ambien CR from Sanofi.
“We are excited at the addition of Ambien to our portfolio,” Apurva Saraf, CEO and president of Cosette, said. “We continue to leverage our demonstrated, best-in-class capabilities in executing complex carve-outs and integrating diverse products. This acquisition not only strengthens our product portfolio, but also reaffirms our commitment to ensuring high-quality products continue to remain available to patients worldwide.”
Annual sales for Ambien and Ambien CR for the 12 months ended in April were $39 million.
The acquisition builds on Cosette’s leading expertise in carving out critical drugs from global pharma companies across Japan, Europe and the U.S. The company’s
strategic approach and industry expertise help it make divestiture and product transition seamless, ensuring uninterrupted access to critical medicines for millions of patients.
